Navigation Links
Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank

KANSAS CITY, Kan. and BOSTON, March 7, 2013 /PRNewswire/ -- Aratana Therapeutics, a biopharmaceutical company developing innovative medicines for cats and dogs (companion animals), today announced it has closed on a $10 million non-dilutive financing with Square 1 Bank, a full service commercial bank dedicated exclusively to serving the financial needs of the venture capital community and entrepreneurs in all stages of growth and expansion.  Proceeds will be used to fund general corporate purposes. 

"We are delighted to have the continued support of Square 1 Bank," stated Steven St. Peter , M.D., President and Chief Executive Officer of Aratana Therapeutics.  "We're grateful Square 1 has remained a supporter of Aratana since its inception and are eager to extend our relationship as we advance our programs."

Scott Foote , senior vice president in Square 1 Bank's Life Sciences practice, added, "We are pleased to provide Aratana with the financing solutions it needs to support future developments in the animal health market, and we look forward to the company's future success."

About Aratana Therapeutics

Aratana Therapeutics is a biopharmaceutical company positioned to deliver high quality new medicines that address significant therapeutic needs for cats and dogs (companion animals).  Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and then develops strategies to maximize the value of the programs for the animal health market.  For more information, please visit

About Square 1 Bank

Square 1 Bank is a full service commercial bank dedicated exclusively to serving the financial needs of the venture capital community and entrepreneurs in all stages of growth and expansion. Square 1's expertise, focus and strong capital base provide flexible resources and unmatched support to meet our clients' needs. The bank offers tailored products and solutions aided by the latest in technological innovations. Square 1 has offices coast to coast in Austin, Boston, Denver, Durham, Los Angeles, New York, San Diego, Seattle, Silicon Valley and Washington, DC. For more information, visit

For Investors & Media:
Tiberend Strategic Advisors, Inc.
Joshua Drumm , Ph.D. / Andrew Mielach; (212) 375-2664; (212) 375-2694

SOURCE Aratana Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
2. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
3. Aratana Therapeutics Completes $15 Million Series B Financing
4. Nasseo, Inc. Joins BioInspire™ Medical Technology Incubator, Closes Seed Funding Round
5. Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
6. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
7. Enviva Closes on $120 Million Senior Secured Credit Facility
8. AyoxxA Biosystems Closes Series A Financing Round
9. OncoSec Closes $7.75 Million Public Offering
10. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
11. Radius Closes $27.65 Million Second Tranche of Previously Announced Financing
Post Your Comments:
(Date:11/30/2015)... DIEGO , Nov. 30, 2015  HUYA Bioscience ... China,s pharmaceutical innovations, today announced it ... Drug Development Fund (KDDF) to foster collaboration between KDDF ... development and commercialization of healthcare products for the global ... as an important source of new innovative preclinical and ...
(Date:11/30/2015)... CA (PRWEB) , ... November ... ... Intelligence Company, today announced tighter software integration with MarkLogic, the Enterprise NoSQL ... organizations maximize information to drive change. , Smartlogic’s Content Intelligence capabilities provide ...
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... 2 nouvelles études permettent d ... différences entre les souches bactériennes retrouvées dans la plaque ... humains . Ces recherches  ouvrent une nouvelle ... charge efficace de l,un des problèmes de santé ... .    --> 2 nouvelles études permettent d ...
Breaking Biology Technology:
(Date:11/17/2015)... -- Paris , qui s,est ... Paris , qui s,est tenu du 17 ... de l,innovation biométrique, a inventé le premier scanner couplé, ... la même surface de balayage. Jusqu,ici, deux scanners étaient ... empreintes digitales. Désormais, un seul scanner est en mesure ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
Breaking Biology News(10 mins):